Literature DB >> 12889565

Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study.

T I Huo1, Y H Huang, J C Wu, P C Lee, F Y Chang, S D Lee.   

Abstract

BACKGROUND: Ultrasound-guided percutaneous ethanol injection (PEI) and percutaneous acetic acid injection (PAI) are effective in the treatment of hepatocellular carcinoma (HCC). We conducted a prospective study to compare the therapeutic efficacy of both these methods.
METHODS: Sixty-three patients were treated by PAI using 50% acetic acid and 62 by PEI using pure ethanol. There were no significant baseline differences in age, sex, Child-Pugh class, tumour size and number, or other clinico-biochemical parameters between the two groups.
RESULTS: During a follow-up period of 24 +/- 9 (range 6-38) months, 19 (30%) of the PAI group and 21 (34%) of the PEI group died (P = 0.704). The 1- and 3-year survival rates were 84% and 51% for the PAI group and 81% and 46% for the PEI group (P = 0.651). The corresponding tumour recurrence rates were 51% and 74% for the PAI group, and 54% and 64% for the PEI group (P = 0.787). The treatment sessions were 3.9 +/- 1.6 and 6.2 +/- 2.3 for the PAI and PEI groups, respectively, in each treatment cycle (P = 0.008). A multivariate analysis using the Cox regression model revealed that ascites (relative risk (RR) 3.1, 95% confidence interval (CI) 1.5-6.3, P = 0.002), large (>3 cm) or multinodular HCCs (RR 2.4, 95% CI 1.1-5.4, P = 0.04), and development of tumour recurrence (RR 7.0, 95% CI 3.1-16.0, P < 0.001) were independent, poor prognostic factors in both groups.
CONCLUSIONS: PAI and PEI are equally effective in the treatment of HCC. PAI has the advantage of fewer treatment sessions in each treatment course. Careful pretreatment patient selection may improve survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12889565     DOI: 10.1080/00365520310003048

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  15 in total

1.  Management of hepatocellular carcinoma: Enlightening the gray zones.

Authors:  Andrea Mancuso
Journal:  World J Hepatol       Date:  2013-06-27

2.  Pathological effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy.

Authors:  A L Baggish; R N Smith; I Palacios; G J Vlahakes; D M Yoerger; M H Picard; P A Lowry; I-K Jang; M A Fifer
Journal:  Heart       Date:  2006-06-28       Impact factor: 5.994

3.  Application of Trifluoroacetic Acid as a Theranostic Agent for Chemical Ablation of Solid Tissue.

Authors:  Samuel A Einstein; Emily A Thompson; Chunxiao Guo; Elizabeth M Whitley; James A Bankson; Erik N K Cressman
Journal:  J Vasc Interv Radiol       Date:  2019-09-16       Impact factor: 3.464

Review 4.  The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations.

Authors:  Ashish Kumar; Subrat K Acharya; Shivaram P Singh; Vivek A Saraswat; Anil Arora; Ajay Duseja; Mahesh K Goenka; Deepali Jain; Premashish Kar; Manoj Kumar; Vinay Kumaran; Kunisshery M Mohandas; Dipanjan Panda; Shashi B Paul; Jeyamani Ramachandran; Hariharan Ramesh; Padaki N Rao; Samir R Shah; Hanish Sharma; Ragesh B Thandassery
Journal:  J Clin Exp Hepatol       Date:  2014-05-22

Review 5.  Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma.

Authors:  Sebastian Weis; Annegret Franke; Thomas Berg; Joachim Mössner; Wolfgang E Fleig; Konrad Schoppmeyer
Journal:  Cochrane Database Syst Rev       Date:  2015-01-26

Review 6.  Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.

Authors:  Davide Roccarina; Avik Majumdar; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-03-10

Review 7.  Role of local ablative therapy for hepatocellular carcinoma.

Authors:  Ragesh B Thandassery; Usha Goenka; Mahesh K Goenka
Journal:  J Clin Exp Hepatol       Date:  2014-04-01

8.  Hepatitis C virus infection is a risk factor for tumor recurrence after resection of small hepatocellular carcinomas.

Authors:  Teh-Ia Huo; Jaw-Ching Wu; Cheng-Yuan Hsia; Gar-Yang Chau; Wing-Yiu Lui; Yi-Hsiang Huang; Pui-Ching Lee; Full-Young Chang; Shou-Dong Lee
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

9.  Techniques of interventional tumor therapy.

Authors:  Andreas H Mahnken; Philipp Bruners; Rolf W Günther
Journal:  Dtsch Arztebl Int       Date:  2008-09-19       Impact factor: 5.594

10.  Deterioration of hepatic functional reserve in patients with hepatocellular carcinoma after resection: incidence, risk factors, and association with intrahepatic tumor recurrence.

Authors:  Teh-Ia Huo; Wing-Yu Lui; Jaw-Ching Wu; Yi-Hsiang Huang; Kuang-Liang King; Che-Chuan Loong; Pui-Ching Lee; Full-Young Chang; Shou-Dong Lee
Journal:  World J Surg       Date:  2004-02-17       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.